Current choice of treatments for neovascular AMD

Expert Review of Clinical Pharmacology

Volumn 8, Issue 1, 2014, Pages 135-140

  Lai, Kevin ^a   Landa, Gennady ^a,b  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Avastin; Eylea; Lucentis; neovascular age related macular degeneration; treatment

Indexed keywords

AFLIBERCEPT; ANKYRIN; BEVACIZUMAB; COMPLEMENT INHIBITOR; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SMALL INTERFERING RNA; SQUALAMINE; VERTEPORFIN; DRUG; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; HUMAN; LASER COAGULATION; PHOTODYNAMIC THERAPY; REVIEW; ANTAGONISTS AND INHIBITORS; WET MACULAR DEGENERATION;

HUMANS; PHARMACEUTICAL PREPARATIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84916928165     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.990379     Document Type: Review

References (51)

1. Congdon N, O'Colmain B, Klaver CC, et al. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85
2. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004;44:17-39
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564-72
4. Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related macular degeneration. Trends Mol Med 2004;10: 417-20
5. Wong TY, Loon SC, Saw SM. The epidemiology of age related eye diseases in Asia. Br J Ophthalmol 2006;90:506-11
6. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1986;104:694-701
7. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1109-14.
8. Erratum in Arch Ophthalmol 1992;110:761
9. Five-year follow-up of fellow eyes of patients with age related macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group. Arch Ophthalmol 1993;111:1189-99
10. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Macular Photocoagulation Study Group. Arch Ophthalmol 1986;104: 503-12
11. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109: 1220-31
12. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007(3):CD004763
13. Lu LPL, Kwok AKH. An update of treatment options for neovascular age-related macular degeneration. Hong Kong Med J 2007;13(6):460-70
14. Kaiser PK. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin 2009;25(8):1853-60
15. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117(10):1329-45
16. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012; 119(5):1001-10
17. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012;119(5):992-1000
18. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27(2):133-40
19. Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012;32(8):1453-64
20. Newsom RS, McAlister JC, Saeed M, McHugh JD. Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation. Br J Ophthalmol 2001;85:173-8.
21. Erratum in Br J Ophthalmol 2001;85:505
22. Lee J, Freeman WR, Azen SP, et al. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina 2007; 27(9):1205-13
23. Freund KB, Mrejen S, Gallego-Pinazo R. An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert Opin Pharmacother 2013;14:1017-28
24. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40: 352-68
25. Hussain AA, Lee Y, Zhang JJ, Marshall J. Disturbed matrix metalloproteinase activity of Bruch's membrane in agerelated macular degeneration. Invest Ophthalmol Vis Sci 2011;52(7):4459-66
26. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27): 2805-16
27. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27(9):1260-6
28. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14):1419-31
29. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14): 1432-44
30. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after single intravitreal injection in humans. Am J Ophthalmol 2008;146(4):508-12
31. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012;154(4): 682-6
32. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011; 151(5):887-95.e1
33. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119(7):1388-98
34. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411
35. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97(3):266-71
36. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32(3):434-57
37. Hanout M, Ferraz D, Ansari M, et al. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. Biomed Res Int 2013;2013:830837
38. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-48
39. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 2014;121(1): 188-92
40. Ophthotech Corp. a phase 1, safety, tolerability and pharmacokinetic profile of intravitreous injections of E10030 (Anti- PDGF pegylated aptamer) in subjects with neovascular age-related macular degeneration. 2012. Available from: http:// clinicaltrials.gov/ct2/show/NCT00569140
41. Ophthotech Corp. A safety and efficacy study of E10030 (Anti-PDGF Pegylated Aptamer) plus lucentis for neovascular age-related macular degeneration. 2012. Available from: http://clinicaltrials.gov/ct2/ show/NCT01089517
42. Kaiser PK. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline. Ophthalmology 2013;120(Suppl 5):S11-15
43. Kaiser PK, Symons RCA, Shah SM, et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 2010;150(1): 33-9
44. Nguyen QD, Schachar RA, Nduaka CI, et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology 2012;119(9):1867-73
45. Efficacy and safety of squalamine lactate eye drops in subjects with neovascular (Wet) age-related macular degeneration (AMD). Available from: http://clinicaltrials.gov/show/ NCT01678963
46. Study of MP0112 intravitreal injection in patients with wet age related macular degeneration. Available from: http:// clinicaltrials.gov/show/NCT01086761
47. Safety and efficacy of oral PTK787 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) (ADVANCE). Available from: http:// clinicaltrials.gov/show/NCT00138632
48. A safety study to evaluate pazopanib eye drops in healthy volunteers. Available from: http://clinicaltrials.gov/show/NCT01072214
49. A multicenter, proof-of-concept study of intravitreal AL-78898A in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD). Available from: http://clinicaltrials.gov/show/ NCT01603043
50. A study of ARC1905 (Anti-C5 Aptamer) in subjects with dry age-related macular degeneration. Available from: http:// clinicaltrials.gov/show/NCT00950638
51. Lux A, Llacer H, Heussen FMA, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-22